FDA to approve third dose of COVID vaccine for immunocompromised people



[ad_1]

The Food and Drug Administration will update its emergency use authorization for the Pfizer and Moderna coronavirus vaccines as early as Thursday to allow immunocompromised people to get a third dose, a source familiar with the matter told Axios.

Why is this important: Data suggests that people with weakened immune systems do not generate sufficiently strong levels of protection against the virus with just two doses, but a third dose could help significantly.

Get market news worthy of your time with Axios Markets. Subscribe for free.

The big picture: Scientists have debated who should get booster shots and when, as the highly contagious Delta variant is increasing the number of new cases across the country.

  • According to the Centers for Disease Control and Prevention (CDC), about 2.7% of American adults are immunocompromised, a group that includes people who are undergoing cancer treatment, living with HIV, or receiving an organ transplant, between others.

  • More than one million people in the United States have received unauthorized recalls of Moderna or Pfizer vaccines according to an internal CDC briefing obtained by ABC News.

Inventory: In July, the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) urged action on additional doses for people with compromised immunity, according to NBC News.

  • In July, Israel became the first country to offer booster shots for people with compromised immune systems and the elderly.

  • Germany and the UK have also announced their intention to offer boosters from September.

  • Yes, but: The World Health Organization has called for a moratorium on booster injections until at least September to allow poorer countries access to doses.

What to watch: ACIP will meet on Friday to make recommendations on booster injections for immunocompromised people.

Go further: The mess of CDC reminder messages

More from Axios: Sign up to get the latest market trends with Axios Markets. Subscribe for free

[ad_2]

Source link